TCTR20230510001
Completed
Not Applicable
Safety and humoral immunogenicity of COVID-19 vaccine against SAR-CoV2 wild type and Omicron variant in patients with solid cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Solid cancerCOVID-19
- Sponsor
- Faculty of Medicine, Chiang Mai University
- Enrollment
- 110
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. age 18 years or above
- •2\. Has an appointment to receive vaccine against SAR\-CoV2
- •3\. Confirmed diagnosis of solid tumor by pathology or imaging with any stages, treatments and responses after treatment that include complete remission disease within 1 year
- •4\. Life expectancy is more than 6 months at the time receiving first dose of vaccine
Exclusion Criteria
- •1\. Previously diagnosed COVID\-19 in the past 90 days
- •2\. High\-risk epidemiology history within 14 days before enrolment e.g. close contact with index cases or visiting/ living in outbreak area
- •3\. Receive blood products, blood components, or immunoglobulin within the past 90 days
- •4\. Receive live attenuated vaccine in the past 28 days
- •5\. Receive inactivated or subunit vaccines in the past 14 days
- •6\. Women in lactation, pregnancy, or planned pregnancy during the study period
- •7\. Known allergy to any vaccine component
- •8\. Has signs and symptoms of active skin infection at injection site
- •9\.Known history of HIV infection
- •10\.Receive immunosuppressive drug
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Immunogenicity and the safety of the COVID-19 vaccines available in Thailand.The immune response after COVID-19 vaccine administration in healthy volunteers.COVID-19 vaccine, Sputnik V, ChAdOx1, coronavac, Sinovac.TCTR20210517006Chulabhorn Royal Academy3,000
Completed
Phase 1
Safety and Immunogenicity of EXG-5003.Prevention for SARS-CoV-2 infection diseaseJPRN-jRCT2041210013Doi Yohei60
Completed
Not Applicable
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in liver transplant recipientsImmunogenicity and safety of SARS-CoV-2 vaccine in liver transplant recipientsliver transplant, vaccine, COVID-19, SARS-CoV-2, safetyTCTR20210526004Faculty of medicine, Chulalongkorn university60
Not yet recruiting
Not Applicable
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in patients with hepatocellular carcinomaImmunogenicity and safety of SARS-CoV-2 vaccine in patients with hepatocellular carcinomaCOVID-19, vaccine, hepatocellular carcinoma, SARS-CoV-2TCTR20210525005Faculty of Medicine, Chulalongkorn university60
Not yet recruiting
Not Applicable
Immunogenicity and safety COVID-19 vaccine in healthy adults: a single institute based cohort studyCOVID-19JPRN-UMIN000043589Saga University60